APPLICATION NUMBER:
21-677

CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)
Drug: ALIMTA

Generic name: Pemetrexed; N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolol[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]-L-glutamic acid; MTA; LY231514;

Formulation: 40 ml aqueous solution of 200 or 1000 mg for intravenous infusion; lyophilized powder of 20, 100 and 500 mg for reconstitution and intravenous infusion.

Indications: ALIMTA as a single agent for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Applicant: Eli Lilly and Company
Indianapolis, IN 46285

OCPB Division: Division of Pharmaceutical Evaluation 1 (HFD-860)

OND Division: Division of Oncology Drug Products (HFD-150)

Submission Dates: 03-NOV-2003

Primary/Pharmacometric Reviewer: Brian Booth, Ph.D.

Pharmacometric Team Leader: Joga Gobburu, Ph.D.

Team Leader: N.A.M. Atiqur Rahman, Ph.D.

Type of Submission: NDA-New Molecular Entity

---

I. Table of Contents

II. Executive Summary
   A. Recommendations 2
   B. Phase 4 Commitments 2

III. Summary of Clinical Pharmacology and Biopharmaceutics Findings 3

IV. Question Based Review 4
II. Executive Summary

The applicant is seeking marketing approval for Alimta as a single-agent for the treatment of patients with locally advanced or metastatic non-small lung cell cancer. Non-inferiority of Alimta to docetaxel could not be determined, but the Oncologic Drugs Advisory Committee agreed with the FDA that the 9.1% response rate and better toxicity profile warranted accelerated approval of Alimta as a single-agent for NSCLC. The applicant demonstrated that cancer type did not alter the pharmacokinetics of Alimta.

**Recommendation:** The Alimta NDA 21-677 is acceptable to the Office of Clinical Pharmacology and Biopharmaceutics.

**Phase 4 Commitments:**

No phase 4 commitments are recommended.
III. Summary of Clinical Pharmacology Findings

Alimta is a novel antimetabolite that inhibits thymidylate synthase, dihydro folate reductase and glycaminamide ribonucleotide formyl transferase, and mediates cell death by inhibiting DNA synthesis. Alimta induced a 9.1 response rate in non-small cell lung cancer (NSCLC) in patients who had failed previous treatments. The main toxicity of Alimta is neutropenia, but leukopenia, thrombocytopenia, stomatitis, vomiting diarrhea and nausea were also noted. The pharmacokinetics of Alimta follow a 2-compartment model, and excretion is predominantly renal. Alimta was not metabolized by any cytochrome P-450, nor did it inhibit any cytochrome P-450 isozyme. Total systemic clearance of Alimta is 91.8 ml/min and is well correlated with glomerular filtration rate and creatinine clearance (CLcr) calculated using the Cockcroft-Gault formula. The elimination half-life is 3.5 hours, and no accumulation was noted. The pharmacokinetics of Alimta were not affected by sex, age or ethnicity. In the current application, the applicant used the previously described and reviewed population pharmacokinetic model and databases to assess whether the pharmacokinetics of Alimta were affected by NCSLC. The results indicated that the CL and central and peripheral volumes of distribution of Alimta were not significantly affected. The sponsor also assessed protein binding at higher concentrations of Alimta. Protein binding decreased to 58% at 1100 ug/ml. However, this concentration corresponds to a dosage that is approximately ten-fold higher than the currently indicated dosage, and does not represent anything that is clinically meaningful. No changes have been made to the pharmacokinetics section of the Alimta label.
IV. Question Based Review

A. General Attributes

What are the highlights of the chemical properties of drug substance and formulation of the drug product?

Alimta (pemetrexed; MTA; LY231514) is antifolate antineoplastic agent similar to methotrexate. The chemical name for ALIMTA is N-[4-[2-amino-4,7-dihydor-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl]ethyl]benzoyl]-L-glutamic acid disodium salt, which has a molecular weight of 597.49. The chemical structure is shown in Figure 1.

![Chemical Structure of Alimta](image)

**Figure 1. The chemical structure of Alimta**

Alimta is available as a lyophilized powder containing 500 mg of Alimta and 500 mg of mannitol. Vials are reconstituted with 20 ml of 0.9% saline (USP) and pH may be adjusted with hydrochloric acid or sodium hydroxide.

What is the putative mechanism of action of Alimta?

Alimta inhibits thymidylate synthase (TS), which is essential for with DNA synthesis, and thereby mediates its cytotoxic activity. Alimta also inhibits dihydrofolate reductase (DHFR), and glycaminide ribonucleotide formyl transferase (GARFT).

B. General Clinical Pharmacology

What is the effectiveness endpoint?

The primary clinical endpoint in the pivotal trial of Alimta vs docetaxel was overall survival. Response rate, response duration and progression-free survival were the secondary endpoints for this study. Responses were defined as complete response (CR),
partial response (PR), stable disease (SD) or progressive disease (PD) based on tumor size assessed by CAT scan. The applicant proposed a non-inferiority analysis, but the interpretation of this analysis was confounded for two reasons. The survival effect of docetaxel from a historical study was believed to be too small (104 patients) to adequately quantify the docetaxel effect, and in the current study 32% of the Alimta patients crossed over to docetaxel following progression. The Oncology Drugs Advisory Committee (July 27, 2004) agreed with the FDA that the secondary endpoint of response rate and the better toxicity profile of Alimta (compared to docetaxel) warranted accelerated approval.

What are the characteristics of the exposure-response relationships of Alimta?

Effectiveness

In the pivotal phase 3 trial, only one dose of Alimta was administered. Consequently, no concentration-effect relationships could be determined because of the narrow range of doses and AUCs available in this study.

Toxicity

Neutropenia
The main toxicity associated with Alimta was hematological. Neutropenia was the most significant toxicity.

Are the pharmacokinetics of Alimta affected by the NSCLC?

No. In order to address this possibility, the applicant used the population pharmacokinetic model and databases of Alimta already described and reviewed in original NDA submission (refer to the Clinical Pharmacology review of NDA 21-462 for details). To determine the effect of disease on Alimta pharmacokinetics, the sponsor used the following function

\[ P = [\text{TVP}(1-\text{IND})+\text{TVP} \cdot \Theta_7 \cdot \text{IND}]e^\theta \]

Where P is the pharmacokinetic parameter that was tested (CL, V1 or V2), and TVP is the typical value of that parameter. IND is an indicator variable that is set to “1” if the cancer being is present, “0” otherwise. \( \Theta_7 \) is the cancer effect factor. If the cancer has no effect, \( \Theta_7 \) equals 1. Increases or decreases indicate the effect on the parameter tested.

A change in the minimum objective function (MOF) of 3.841 was considered statistically significant, however, only CL changes of >20 % or V changes of >40 % were considered clinically significant.

Thirty-five Australian patients were excluded from the study because a different method of serum creatinine measurement was used in these patients, and the subsequent creatinine clearance and Alimta systemic clearance were demonstrated to be significantly different from the remaining 252 patients by 20 %.
The analysis indicated that CL of Alimta was unaffected by NSCLC (change in MOF was 2.486). These results are presented graphically below.

Figure 9.2. Overlay plots: LY231514 CL versus CrCl\textsubscript{CO\textsubscript{2}}

---

NSCLC reduced the MOF on V1 by 32.321. $\Theta_7$ was 0.75 (95% CI 0.683 to 0.831), indicating approximately 25% reduction in volume, which according to the predefined criteria, was not considered significant. NSCLC had no significant effect on V2 (change in MOF of -0.319).
Is there additional information regarding protein binding?

Yes. Previous protein binding studies for Alimta indicate 80% binding at the dosage indicated for malignant pleural mesothelioma and NSCLC (500 mg/m²). The sponsor conducted a phase 1 study in Japanese patients, who were treated with dosages of Alimta up to 1200 mg/m². Maximal Alimta concentrations at this dose were 212 μg/ml, whereas maximal plasma concentrations at the 500 mg/m² are approximately 100 μg/ml. The applicant investigated the protein binding of Alimta at higher concentrations to assess protein binding at dosages of Alimta greater than 500 mg/m². The applicant studied protein binding at 220, 440, 660, 880 and 1100 μg/ml of Alimta, by incubating radiolabeled compound in plasma for 1 hour at 37°C. The extent of protein binding was determined by ultracentrifugation, and liquid scintillation counting. These studies indicated that protein binding decreased from 77% at 220 μg/ml, to 58% at 1100 μg/ml. However, the decrease in protein binding (20%) is not likely to be clinically significant. In patients with moderate renal impairment, the Alimta AUC increased by 100% without any corresponding increase in toxicity. Therefore the small change in protein binding that occurs from increasing the dose from 500 to 1200 mg/m² (80% at Cmax 100 μg/ml compared to 77% at 220 μg/ml) is not significant. Furthermore, the dosage of Alimta indicated for NSCLC is the same as for malignant pleural mesothelioma (500 mg/m²). Therefore, labeling changes for protein binding also appear unwarranted.
V. Detailed labeling Recommendations

None.
20 Page(s) Withheld

___ § 552(b)(4) Trade Secret / Confidential

___ § 552(b)(4) Draft Labeling

X § 552(b)(5) Deliberative Process

Withheld Track Number: Clin Pharm/Bio-_______
**B. NDA Filing Form**

Office of Clinical Pharmacology and Biopharmaceutics  
*New Drug Application Filing and Review Form*

<table>
<thead>
<tr>
<th>General Information About the Submission</th>
<th>Information</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA Number</td>
<td>21677</td>
<td>Brand Name</td>
</tr>
<tr>
<td>OCPB Division (I, II, III)</td>
<td>1</td>
<td>Generic Name</td>
</tr>
<tr>
<td>Medical Division</td>
<td>Oncology (HFD-150)</td>
<td>Drug Class</td>
</tr>
<tr>
<td>OCPB Reviewer</td>
<td>Brian Booth</td>
<td>Indication(s)</td>
</tr>
<tr>
<td>OCPB Team Leader</td>
<td>Atik Rahman/Joga Gobburu</td>
<td>Dosage Form</td>
</tr>
<tr>
<td>Date of Submission</td>
<td>04-NOV-2003</td>
<td>Dosing Regimen</td>
</tr>
<tr>
<td>Estimated Due Date of OCPB Review</td>
<td></td>
<td>Route of Administration</td>
</tr>
<tr>
<td>PDUFA Due Date</td>
<td>04-SEP-2004</td>
<td>Sponsor</td>
</tr>
<tr>
<td>Division Due Date</td>
<td></td>
<td>Priority Classification</td>
</tr>
</tbody>
</table>

**Clin. Pharm. and Biopharm. Information**

<table>
<thead>
<tr>
<th>STUDY TYPE</th>
<th>&quot;X&quot; if included at filing</th>
<th>Number of studies submitted</th>
<th>Number of studies reviewed</th>
<th>Critical Comments if any</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents present and sufficient to locate reports, tables, data, etc.</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tabular Listing of All Human Studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPK Summary</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference Bioanalytical and Analytical Methods</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Clinical Pharmacology

- Mass balance: na
- Isoenzyme characterization: na
- Blood/plasma ratio: na
- Plasma protein binding: x 1

**Healthy Volunteers**

- Single dose: na
- Multiple dose: na

**Patients**

- Single dose: x 3
- Multiple dose: x 10

**Dose proportionality**

- Fasting / non-fasting single dose: na
- Fasting / non-fasting multiple dose: na

**Drug-drug interaction studies**

- In-vivo effects on primary drug: na
- In-vivo effects of primary drug: na
- In-vitro: na

**Subpopulation studies**

- Ethnicity: na
- Gender: Na
- Pediatrics: Na
- Geriatrics: Na
- Renal impairment: Na
- Hepatic impairment: na

**PD:**

- Phase 2:
- Phase 3:

**PK/PD:**
<table>
<thead>
<tr>
<th>Phase 1 and/or 2, proof of concept:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 3 clinical trial:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population Analyses -</td>
<td>Data rich: x</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Data sparse: no</td>
<td></td>
</tr>
<tr>
<td>II. Biopharmaceutics</td>
<td>Absolute bioavailability: na</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative bioavailability -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>solution as reference: na</td>
<td></td>
</tr>
<tr>
<td></td>
<td>alternate formulation as reference: na</td>
<td></td>
</tr>
<tr>
<td>Bioequivalence studies -</td>
<td>traditional design; single / multi dose: na</td>
<td></td>
</tr>
<tr>
<td></td>
<td>replicate design; single / multi dose: na</td>
<td></td>
</tr>
<tr>
<td>Food-drug interaction studies:</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>Dissolution:</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>(IVIVC):</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>Bio-wavier request based on BCS</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>BCS class</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>III. Other CPB Studies</td>
<td>Genotype/phenotype studies: na</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronopharmacokinetics</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>Pediatric development plan</td>
<td>na</td>
</tr>
<tr>
<td>Literature References</td>
<td>x</td>
<td>12</td>
</tr>
<tr>
<td>Total Number of Studies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fidelity and QBR comments**

<table>
<thead>
<tr>
<th>Application filed?</th>
<th>&quot;X&quot; if yes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x</td>
<td>Reasons if the application is not filed (or an attachment if applicable) For example, is clinical formulation the same as the to-be-marketed one?</td>
</tr>
<tr>
<td>Comments sent to firm?</td>
<td>no</td>
<td>Comments have been sent to firm (or attachment included). FDA letter date if applicable.</td>
</tr>
<tr>
<td>QBR questions (key issues to be considered)</td>
<td>Are the pharmacokinetics of Alimta in NSCLC the same as the Alimta kinetics in mesothelioma?</td>
<td></td>
</tr>
<tr>
<td>Other comments or information not included above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary reviewer Signature and Date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary reviewer Signature and Date</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CC: NDA XX-XXX, HFD-850(P. Lee), HFD-860 (M. Mehta), HFD-XXX(CSO), HFD-8XX(TL, DD, DDD), CDR
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Brian Booth
8/13/04 12:02:28 PM
BIOPHARMACEUTICS

Jogarao Gobburu
8/13/04 01:31:23 PM
BIOPHARMACEUTICS

Atiqur Rahman
8/18/04 10:27:11 AM
BIOPHARMACEUTICS